213 related articles for article (PubMed ID: 10836289)
21. [123I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics.
Klemm E; Grünwald F; Kasper S; Menzel C; Broich K; Danos P; Reichmann K; Krappel C; Rieker O; Briele B; Hotze AL; Möller HJ; Biersack HJ
Am J Psychiatry; 1996 Feb; 153(2):183-90. PubMed ID: 8561197
[TBL] [Abstract][Full Text] [Related]
22. Attentional improvement following quetiapine fumarate treatment in schizophrenia.
Sax KW; Strakowski SM; Keck PE
Schizophr Res; 1998 Oct; 33(3):151-5. PubMed ID: 9789907
[TBL] [Abstract][Full Text] [Related]
23. Typical antipsychotic drugs -- D(2) receptor occupancy and depressive symptoms in schizophrenia.
Bressan RA; Costa DC; Jones HM; Ell PJ; Pilowsky LS
Schizophr Res; 2002 Jul; 56(1-2):31-6. PubMed ID: 12084417
[TBL] [Abstract][Full Text] [Related]
24. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.
Small JG; Hirsch SR; Arvanitis LA; Miller BG; Link CG
Arch Gen Psychiatry; 1997 Jun; 54(6):549-57. PubMed ID: 9193196
[TBL] [Abstract][Full Text] [Related]
25. A case of tardive dystonia successfully managed with quetiapine.
Sasaki Y; Kusumi I; Koyama T
J Clin Psychiatry; 2004 Apr; 65(4):583-4. PubMed ID: 15119928
[No Abstract] [Full Text] [Related]
26. [Utility of quetiapine in tardive dyskinesia].
Navarro Pacheco BV; Montejo González AL; Martín Carrasco M
Actas Esp Psiquiatr; 2003; 31(6):347-52. PubMed ID: 14639511
[TBL] [Abstract][Full Text] [Related]
27. Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia.
Conley RR; Kelly DL; Nelson MW; Richardson CM; Feldman S; Benham R; Steiner P; Yu Y; Khan I; McMullen R; Gale E; Mackowick M; Love RC
Clin Neuropharmacol; 2005; 28(4):163-8. PubMed ID: 16062094
[TBL] [Abstract][Full Text] [Related]
28. Quetiapine, clozapine, and olanzapine in the treatment of tardive dyskinesia induced by first-generation antipsychotics: a 124-week case report.
Sacchetti E; Valsecchi P
Int Clin Psychopharmacol; 2003 Nov; 18(6):357-9. PubMed ID: 14571157
[TBL] [Abstract][Full Text] [Related]
29. Can atypical antipsychotics improve tardive dyskinesia associated with other atypical antipsychotics? Case report and brief review of the literature.
Peritogiannis V; Tsouli S
J Psychopharmacol; 2010 Jul; 24(7):1121-5. PubMed ID: 19395427
[TBL] [Abstract][Full Text] [Related]
30. High central D2-dopamine receptor occupancy as assessed with positron emission tomography in medicated but therapy-resistant schizophrenic patients.
Coppens HJ; Slooff CJ; Paans AM; Wiegman T; Vaalburg W; Korf J
Biol Psychiatry; 1991 Apr; 29(7):629-34. PubMed ID: 1675892
[TBL] [Abstract][Full Text] [Related]
31. Quetiapine-related tardive dyskinesia.
Ghaemi SN; Ko JY
Am J Psychiatry; 2001 Oct; 158(10):1737. PubMed ID: 11579018
[No Abstract] [Full Text] [Related]
32. Tardive dyskinesia in older patients.
Jeste DV
J Clin Psychiatry; 2000; 61 Suppl 4():27-32. PubMed ID: 10739328
[TBL] [Abstract][Full Text] [Related]
33. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.
Tauscher J; Hussain T; Agid O; Verhoeff NP; Wilson AA; Houle S; Remington G; Zipursky RB; Kapur S
Am J Psychiatry; 2004 Sep; 161(9):1620-5. PubMed ID: 15337652
[TBL] [Abstract][Full Text] [Related]
34. Re: Klintenberg et al, tardive dyskinesia model in the common marmoset.
Friedman JH
Mov Disord; 2003 Jan; 18(1):114-5. PubMed ID: 12518311
[No Abstract] [Full Text] [Related]
35. Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine.
Seeman P; Tallerico T
Am J Psychiatry; 1999 Jun; 156(6):876-84. PubMed ID: 10360126
[TBL] [Abstract][Full Text] [Related]
36. Quetiapine: efficacy and tolerability in schizophrenia.
Kasper S; Tauscher J; Heiden A
Eur Neuropsychopharmacol; 2001 Oct; 11 Suppl 4():S405-13. PubMed ID: 11587888
[TBL] [Abstract][Full Text] [Related]
37. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients.
Spivak B; Mester R; Abesgaus J; Wittenberg N; Adlersberg S; Gonen N; Weizman A
J Clin Psychiatry; 1997 Jul; 58(7):318-22. PubMed ID: 9269253
[TBL] [Abstract][Full Text] [Related]
38. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study.
Mullen J; Jibson MD; Sweitzer D
Clin Ther; 2001 Nov; 23(11):1839-54. PubMed ID: 11768836
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
[TBL] [Abstract][Full Text] [Related]
40. FDA advisers wary of expanding quetiapine use: clinicians air concerns about metabolic effects, tardive dyskinesia.
Traynor K
Am J Health Syst Pharm; 2009 May; 66(10):880, 882. PubMed ID: 19420301
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
